Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,033 USD | +0.86% |
|
-1.52% | +17.85% |
03/07 | Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval | MT |
03/07 | Sanofi obtains EU approval for Dupixent | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.85% | 11TCr | |
+16.90% | 12TCr | |
+17.23% | 2.6TCr | |
-24.37% | 1.93TCr | |
-18.56% | 1.6TCr | |
-18.31% | 1.57TCr | |
-47.75% | 1.45TCr | |
+57.25% | 1.45TCr | |
+5.31% | 1.39TCr | |
+116.39% | 999.6Cr |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. - Special Call